Vaccines for Animal Viral Infections

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 8668

Special Issue Editors


E-Mail Website
Guest Editor
Chinese Academy of Agricultural Sciences, Beijing, China
Interests: african swine fever virus
Institute of Animal Science and Veterinary Medicine, Shanghai Academy of Agricultural Sciences, Shanghai, China
Interests: coronaviruses; swine RNA virus; hepatitis e virus; apoptosis; molecular virology; infection and immunity; porcine epidemic diarrhea virus (PEDV)

Special Issue Information

Dear Colleagues,

It is well known that the unbridled spread of animal viruses can pose a serious threat to human health, especially some novel and re-emerging animal viruses, some of which have the potential for cross-species transmission to humans. Given the current "One Health" concept, the effective prevention of animal viral diseases is of great public health importance, and vaccination is, without doubt, the most cost-effective means of preventing, controlling and even eradicating infectious animal viral diseases. Therefore, the development of safe and effective vaccines against animal viral diseases is an effective tool and an important strategy to combat viral infections in animals.

In this Special Issue, we invite the submission of original research papers and review articles spanning the entire spectrum of animal viral vaccines including (but are not limited to): Progress and challenges in animal viral vaccine development; new technologies used in the development of animal viral vaccines; methods and means of evaluating the vaccination effect; different vaccination routes on the immunization effect; multivalence combined vaccine in animal viral vaccine development; the importance of the vaccine types and current status on companion animal viral vaccines.

Dr. Dongming Zhao
Dr. Fusheng Si
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal viral vaccine 
  • safety and efficacy 
  • vaccine policy 
  • One Health 
  • vaccination routes 
  • combined vaccine 
  • companion animal vaccines 
  • public health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3559 KiB  
Article
Evaluation of Vaccine Strains Developed for Efficient, Broad-Range Protection against Foot-and-Mouth Disease Type O
by Seong Yun Hwang, Sung Ho Shin, Hyun Mi Kim, SeHee Shin, Min Ja Lee, Su-Mi Kim, Jong-Soo Lee and Jong-Hyeon Park
Vaccines 2023, 11(2), 271; https://doi.org/10.3390/vaccines11020271 - 27 Jan 2023
Cited by 2 | Viewed by 2223
Abstract
Foot-and-mouth disease (FMD) type O includes 11 genetic topotypes. The Southeast Asia (SEA), Middle East–South Asia (ME-SA), and Cathay topotypes belong to FMD type O and occur frequently in Asia. Therefore, it is necessary to develop a potent vaccine strain with a broad [...] Read more.
Foot-and-mouth disease (FMD) type O includes 11 genetic topotypes. The Southeast Asia (SEA), Middle East–South Asia (ME-SA), and Cathay topotypes belong to FMD type O and occur frequently in Asia. Therefore, it is necessary to develop a potent vaccine strain with a broad antigenic coverage in order to provide complete protection against these three topotypes. In this study, an experimental vaccine was produced using chimeric vaccine strains (JC-VP1 or PA2-VP1) that contained VP4, VP2, and VP3 of the ME-SA topotype (O Manisa) and VP1 of the SEA topotype (Mya98 lineage; O/SKR/Jincheon/2014) or ME-SA topotype (PanAsia2 lineage; O/PAK/44). Mice were immunized with the experimental vaccines, and they were fully protected against the three topotypes. The neutralizing antibody titers of PA2-VP1 were significantly higher than those of JC-VP1 in the early vaccination phase in pigs. Here, we confirmed complete protection in pigs vaccinated with JC-VP1 or PA2-VP1, when challenged against the SEA (O/SKR/Jincheon/2014), ME-SA (O/SKR/Boeun/2017) and Cathay (O/Taiwan/97) topotype viruses, with moderately higher protection provided by PA2-VP1 than by JC-VP1. Full article
(This article belongs to the Special Issue Vaccines for Animal Viral Infections)
Show Figures

Figure 1

Review

Jump to: Research

31 pages, 2749 KiB  
Review
Towards a Safer Future: Enhancing Vaccine Development to Combat Animal Coronaviruses
by Fusheng Si, Ruisong Yu, Shijuan Dong, Bingqing Chen, Chunhua Li and Shuai Song
Vaccines 2024, 12(3), 330; https://doi.org/10.3390/vaccines12030330 - 19 Mar 2024
Cited by 1 | Viewed by 2147
Abstract
Coronaviruses (CoVs) are a large class of positively stranded RNA viruses that pose a significant threat to public health, livestock farming, and wild animals. These viruses have the ability to cross species barriers and cause devastating epidemics. Animals are considered to be intermediate [...] Read more.
Coronaviruses (CoVs) are a large class of positively stranded RNA viruses that pose a significant threat to public health, livestock farming, and wild animals. These viruses have the ability to cross species barriers and cause devastating epidemics. Animals are considered to be intermediate hosts for many coronaviruses, and many animal coronaviruses also have the potential for cross-species transmission to humans. Therefore, controlling the epidemic transmission of animal coronaviruses is of great importance to human health. Vaccination programs have proven to be effective in controlling coronaviruses infections, offering a cost-effective approach to reducing morbidity and mortality, so the re-emergence of lethal coronaviruses emphasizes the urgent need for the development of effective vaccines. In this regard, we explore the progress in animal coronavirus vaccine development, covering the latest taxonomy of the main animal coronaviruses, spillover events, diverse vaccine development platforms, potential main targets for animal coronavirus vaccine development, and primary challenges facing animal coronavirus vaccines. We emphasize the urgent need to create a “dual-effect” vaccine capable of eliciting both cellular and humoral immune responses. The goal is to highlight the contributions of veterinary scientists in this field and emphasize the importance of interdisciplinary collaboration between the veterinary and medical communities. By promoting communication and cooperation, we can enhance the development of novel and super vaccines to combat human and animal coronavirus infections in the future. Full article
(This article belongs to the Special Issue Vaccines for Animal Viral Infections)
Show Figures

Figure 1

22 pages, 395 KiB  
Review
Vaccination Failures in Pigs—The Impact of Chosen Factors on the Immunisation Efficacy
by Agata Augustyniak and Małgorzata Pomorska-Mól
Vaccines 2023, 11(2), 230; https://doi.org/10.3390/vaccines11020230 - 19 Jan 2023
Cited by 5 | Viewed by 3085
Abstract
Infectious diseases that often lead to economic losses still pose a severe problem in the pig production sector. Because of increasing restrictions on antibiotic usage, vaccines may become one of the major approaches to controlling infectious diseases; much research has proved that they [...] Read more.
Infectious diseases that often lead to economic losses still pose a severe problem in the pig production sector. Because of increasing restrictions on antibiotic usage, vaccines may become one of the major approaches to controlling infectious diseases; much research has proved that they could be very efficient. Nevertheless, during their life, pigs are exposed to various factors that can interfere with vaccination efficacy. Therefore, in the present paper, we reviewed the influence of chosen factors on the pig immunisation process, such as stress, faecal microbiota, host genetics, the presence of MDAs, infections with immunosuppressive pathogens, and treatment with antibiotics and mycotoxins. Many of them turned out to have an adverse impact on vaccine efficacy. Full article
(This article belongs to the Special Issue Vaccines for Animal Viral Infections)
Back to TopTop